Culverwell Anthony James
Culverwell Anthony James, DIR, reported a transaction classified as grant at Quoin Pharmaceuticals, Ltd. involving 31352.000000 shares for an estimated $161462.80. Reported holdings after the transaction were 34218.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Aug 27, 2026
- Filing date
- Aug 28, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
QNRX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0001104659-26-103374 ADSs
- Transaction date
- Aug 27, 2026 Filed Aug 28, 2026, 10:39 PM · 1d delay
- Shares
- 31,352 sh $5.15 per share
- Estimated value
- $161k Computed from shares × price
- Holdings after
- 34,218 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-12 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 1
Filing reported within two business days of the transaction. - grant_or_award-22 points
transaction_code = A
Grant or award transactions are scheduled compensation, not discretionary.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.
- F2
On August 27, 2026, the Issuer and the Reporting Person, entered into an exchange agreement, pursuant to which $161,461 of accrued interest outstanding ("Outstanding Debt") owed in connection with a n…
0 other transactions
0 recent txs